Overview

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Status:
COMPLETED

Trial end date:
2024-10-04

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to show equivalence in pharmacokinetics (PK) of BIIB800 and Actemra following SC administration of a single dose to healthy male participants. The secondary objective of the study is to evaluate PK over time, clinical safety, pharmacodynamic (PD) profiles and immunogenicity of BIIB800 and Actemra.

Phase:

PHASE1

Details

Lead Sponsor:

Biogen

Treatments:

tocilizumab